TMCnet News
Exact Sciences Names Scott Coward as General CounselExact Sciences Corp. (NASDAQ: EXAS) today announced that Scott Coward has been named Senior Vice President and General Counsel for the company effective January 1, 2015. "Scott is a talented lawyer whose extensive legal and healthcare industry expertise makes him a perfect fit for our rapidly growing business," said Kevin Conroy, president, CEO and chairman of Exact Sciences. "His passion for healthcare innovation will fit seamlessly into our culture. He will be an important asset to our leadership team as we continue to work to broaden patient and provider access to Cologuard, the first FDA-approved noninvasive stool DNA colorectal cancer screening test, as well as develop new cancer screening technologies." Coward brings with him decades of experience working with large corporations and emerging growth healthcare companies. Most recently, he was managing partner of K&L Gates' Raleigh, N.C. office with a specialization in corporate, securities and M&A for life sciences companies. Coward counseled pharmaceutical and biotechnology companies spanning multiple disease states in areas including R&D, complex licensing, healthcare data and intellectual property. Prior to his tenure with K&L Gates, Coward held roles as General Counsel at Blue Rhino Corporation, Associate General Counsel at GE Medical Systems Information Technologies and Partner at Smith Anderson, one of the largest law firms in North Carolina. "I am honored to join Exact Sciences at this key time in the company's history," Coward said. "Exact Sciences has tremendous opportunities ahead of it and I am pleased to join the company as it continues to build momentum for Cologuard while fostering its product development pipeline." Coward received a B.S. in Business Administration from the University of North Carolina at Chapel Hill and hs J.D. from Columbia University School of Law. Available by prescription through a health care provider, Exact Sciences' Cologuard is intended for people 50 years and older who are at average risk for colorectal cancer. It is designed to detect DNA alterations and blood released from cancer and precancerous colon lesions. The screening test is easy to use, does not require medication, dietary restrictions or bowel preparation, and can be completed in the privacy of a patient's home. Cologuard is included in the American Cancer Society's Colorectal Cancer Prevention and Early Detection national guidelines. For more information on Cologuard, visit www.CologuardTest.com or call 1-844-870-8870. Rx Only
About Exact Sciences Corp. Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
|
